APOLLO LIFE SCIENCES LIMITED(AOP)

name changed to Apollo Consolidated Limited

releases a consolidation (1 for 20) timetable and that resolutions considered at the meeting yesterday were passed

a General Meeting is to be held at 11:00 am (EST), on 4 August 2009 at the offices of Pitcher Partners, Level 22 MLC Centre, 19 Martin Place, Sydney, New South Wales to consider the restructure (including a consolidation of 1 for 20) and recapitalisation of the company

the Deed Administrators report that creditors have resolved to accept a recapitalisation proposal

the Deed Administrators report that Apollo's plant & equipment has been sold by auction and the marketing of its intellectual property continues - they are currently negotiating a proposal for the recapitalisation of Apollo - shareholders will be contacted with full details of the recapitalisation proposal shortly

company enters into a Deed of Company Arrangement (DOCA) - the DOCA allows David Young and Anthony Elkerton, the Joint Deed Administrators time to conclude their investigations into Apollo's affairs and conclude their dealings in relation to the sale of Apollo's assets and/or restructure of its share capital with a view to re-listing Apollo on the ASX for the benefit of creditors and shareholders - the deadline for offers to be received for Apollo's assets is 16 January 2009

creditors resolve to enter into a Deed of Company arrangement

the administrators are offering the major assets of the company and its subsidiaries for sale

company appoints administrators Anthony Elkerton and David Young of Pitcher Partners - this is never good for shareholders but it will be a month or so before a clearer picture emerges

funding of $2m from John Priest previously reported as being secured is now not going to proceed

releases preliminary final report

none of the resolutions considered at today's general meeting were approved

a general meeting of Apollo Life Sciences Limited ("Company") will be held on 19 August 2008 at 10.00 a.m. at 147 Queen Street, Beaconsfield NSW 2015

company confirms the restructuring phase of its three-phase program is almost complete and the consolidation phase about to begin

company advises a meeting of shareholders has been requisitioned and it will advise details to shareholders later

advises of the signing of an agreement regarding the licensing of its research proteins business

announces the signing of a Heads of Agreement regarding the licensing of its research proteins business

releases its quarterly cash report to 31 March 2008 showing a deficit at operating level for the quarter of $1.78m

company announces it has engaged Deloitte Touche Tohmatsu to advise the Apollo Board of Directors on their restructure of the Apollo business and in particular the strategic sale of certain business assets owned by Apollo

the company confirms that it is currently implementing its notified restructure strategy with a three stage process of restructuring, consolidation and value-creation - the restructuring, which includes the orderly realisation of non-core assets as a going concern with an aim to pay creditors in full, is scheduled to continue through to June

Apollo is implementing its notified strategy of reducing costs and realising non-core assets - as part of the cost reduction process, the retainer-based contracts of Diabetes Advisory Board members which expired in March have not been renewed - the majority of full scientific advisory board members, including researchers with expertise in the diabetes field, are engaged on a different basis and continue in their roles

securities of Apollo Life Sciences Limited (the "Company") will be suspended from quotation immediately, at the request of the Company in accordance with listing rule 17.2, following the Company's announcement in relation to a strategic review involving the sale of assets and uncertainty relating to the ability of the Company to operate as a going concern